Overview

RENCAREX® (WX-G250) is a targeted antibody for the treatment of solid tumours. The G250 antibody was originally developed at the University of Leiden, Netherlands, by a team led by Prof. Sven Warnaar, who joined WILEX in 1999 and served as the Company’s Chief Scientific Officer until he retired in June 2003.

RENCAREX® is currently in a pivotal Phase III trial as an adjuvant therapy of patients with non-metastatic clear cell renal cell cancer (ccRCC). In Phase I and II studies with more than 100 ccRCC patients completed, RENCAREX® has shown good safety and tolerability and a promising efficacy profile.

Poster:
ASCO 2003: WX-G250 phase II study (monotherapy)
ASCO 2004: WX-G250 phase I/II study (combination with IFNa-2a)
KCS 2006: WX-G250/IFNa-2a phase I/II study prolongs survival
AUA 2007: WX-G250/IFNa-2a or IL-2 phase I/II trials update survival data
KCS 2007: Review of WX-G250/IFNa-2a or IL-2 phase I/II trials
SUO 2007: Review of WX-G250/IFNa-2a or IL-2 phase I/II trials